• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.16
• /
• pp.7085-7088
• /
• 2015

Background: The high incidence of prostate cancer as the most common malignancy in males in many countries raises the question of developing reliable detection tests. The prostate specific antigen (PSA) test is the most widely used for screening for prostate cancer; however, its low specificity elevates the number of unnecessarily biopsies. Serum human kallikrein-2 (hK2) is considered as a promising marker, and especially its ratio to fPSA, for predicting the presence of malignancy to select the best choice referring to biopsy or surveillance. In this study, we investigated the role of hK2 and its combinations with other markers to discriminate prostate cancer from benign diseases in Syrian patients. Materials and Methods: In this prospective oriented cross-sectional cohort study, serum samples were collected from patients referred to many Hospitals in Damascus, Syria, between May 2011 and March 2012, and diagnosed with biopsy proven benign prostate hyperplasia (BPH) or prostate cancer (PCa). Serum was analyzed for hK2, PSA and fPSA, and the ratios of fPSA/PSA and hK2/fPSA were calculated. Results: We found that mean hK2/fPSA ratios were significantly higher (P=0.01) in prostate cancer patients than in the BPH or control groups. Also the ratio hk2/fPSA gave the largest area under the curve (AUC:0.96) which was significantly larger than for fPSA/PSA (AUC:0.41) indicative of higher specificity. Conclusions: Our results demonstrate that the ratio of hK2/fPSA might be superior to the use of fPSA/PSA alone. The hK2 could be shown to enhance the early detection of prostate cancer; especially the ratio hK2/fPSA improves specificity and hence may reduce the number of negative biopsies.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.11
• /
• pp.6929-6933
• /
• 2013

Background: Multiple etiologies have been hypothesized for prostate cancer, including genetic defects and infectious agents. A recently reported gamaretrovirus, xenotropic murine leukemia virus-related virus (XMRV) has been reported to be detected in prostate cancer. However, this virus has not been detected in similar groups of patients in other studies. Herein, we sought to detect XMRV in prostate cancers and benign controls in Sanandaj, west of Iran. Materials and Methods: In a case-control study, genomic DNA was extracted from formalin fixed and paraffin embedded prostate tissues from a total of 163 Iranian patients. We developed a conventional and a nested PCR assay using primers targeting to an env specific sequence of XMRV. PCR assays were carried out on 63 prostate cancers and 100 benign prostate hyperplasias. Results: Beta-actin sequences were successfully detected in the DNA extracts from all prostate tissues, confirming DNA extraction integrity. We did not detect XMRV in samples either from prostate cancers or benign prostate hyperplasias using XMRV specific primers. Conclusions: We conclude that in our population XMRV does not play a role in genesis of prostate cancer.

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.13
• /
• pp.5377-5383
• /
• 2015

Background: Participation is one of the major factors affecting the long-term success of population-based prostate cancer screening programs. The aim of this study was to explore strong factors linked to participation in prostate cancer screening among older Jordanian adults using the Health Belief Model (HBM). Materials and Methods: Data were obtained from Jordanian older adults, aged 40 years and over, who visited a comprehensive health care center within the Ministry of Health. A pilot test was conducted to investigate the internal consistency of the the Champion Health Belief Model Scale for prostate cancer screening and the clarity of survey questions. Sample characteristics and rates of participation in prostate cancer screening were examined using means and frequencies. Important factors associated with participation in prostate cancer screening were examined using bivariate correlation and multivariate logistic regression analysis. Results: About 13% of the respondents had adhered to prostate cancer screening guidelines over the previous decade. Four out of the seven HBM-driven factors (perceived susceptibility, benefits and barriers to PSA test, and health motivation) were statistically significant. Those with greater levels of susceptibility, benefits of PSA test and health motivation and lower levels of barriers to PSA testing were more likely to participate in prostate cancer screening. Family history, presence of urinary symptoms, age, and knowledge about prostate cancer significantly predicted the participation in prostate cancer screening. Conclusions: Health professionals should focus more on the four modifiable HBMrelated factors to encourage older adults to participate in prostate cancer screening. Intervention programs, which lower perceived barriers to PSA testing and increase susceptibility, benefits of PSA testing and health motivation, should be developed and implemented.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.8
• /
• pp.4779-4783
• /
• 2013

Background: This study aimed to evaluate the baseline white blood cell (WBC), neutrophil, lymphocyte, monocyte, basophil, eosinophil count, total prostate-specific antigen (TPSA), free PSA (FPSA) level, neutrophilto- lymphocyte and neutrophil-to-monocyte ratios among patients with prostate cancer and benign prostatic hyperplasia (BPH), as well as healthy individuals. Materials and Methods: 2005-2012 laboratory files of 160 patients with prostate cancer at Kayseri Training and Research Hospital, Oncology Outpatient Clinic, 285 patients who were pathologically diagnosed with BPH in Urology Outpatient Clinic and 200 healthy individuals who were admitted to Internal Medicine Outpatient Clinic were retrospectively analyzed. Baseline WBC, neutrophil, lymphocyte, monocyte, basophil, eosinophil count, TPSA, FPSA level, neutrophil-to-lymphocyte ratio and neutrophil-to-monocyte ratio were recorded and compared across groups. Results: Patients with prostate cancer had a lower lymphocyte level compared to the patients with BPH and healthy controls (p<0.001). The mean monocyte count, leukocyte-to-monocyte ratio, and leukocyte-to-lymphocyte ratio were higher in patients with prostate cancer, but without significance. The mean WBC and leukocyte count were lower in patients with prostate cancer, but again without statistical significance (p=0.130). The mean TPSA and FPSA were 39.4 and 5.67, respectively in patients with prostate cancer, while they were 5.78 and 1.28 in patients with BPH. There was a significant difference in the mean TPSA and FPSA levels between the patient groups (p<0.001). Conclusions: Our study results showed that patients with prostate cancer had a lower level of lymphocytes, neutrophils and WBCs and a higher level of monocytes with a significant difference in lymphocyte count, compared to healthy controls. We suggest that lymphocyte count may be used in combination with other parameters in the diagnosis of prostate cancer, thanks to its ease of assessment.

• Journal of the Korea Institute of Information and Communication Engineering
• /
• v.26 no.6
• /
• pp.865-871
• /
• 2022

In this paper, we propose a method of extracting prostate region using morphological characteristics of ultra-sonic image of prostate. In the first step of the proposed method, the edge area of the prostate image is extracted. The histogram of ultra-sonic image is used to extract base objects to detect the upper edge of prostate region by altering the contrast of the image, then, the lower edges of the extracted base objects are connected by using monotone cubic spline interpolation to extract the upper edge. Step 2, Otsu's binarization is applied to the region under the extracted upper edge of the prostate ultra-sonic image to extract the lower edge of prostate. In the last step, the upper and the lower edges are connected to extract prostate region and by comparing the extracted region of prostate with the one measured manually, the result showed that the morphological characteristics of prostate in ultrasonic image can be utilized to extract the prostate region.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.20
• /
• pp.8699-8703
• /
• 2014

18-fluoro-2-deoxyglucose positron emission tomography-computed tomography ($^{18}F$-FDG PET/CT) scans are commonly used for the staging and restaging of various malignancies, such as head and neck, breast, colorectal and gynecological cancers. However, the value of FDG PET/CT for detecting prostate cancer is unknown. The aim of this study was to evaluate the clinical value of incidental prostate $^{18}F$-FDG uptake on PET/CT scans. We reviewed $^{18}F$-FDG PET/CT scan reports from September 2009 to September 2013, and selected cases that reported focal/diffuse FDG uptake in the prostate. We analyzed the correlation between $^{18}F$-FDG PET/CT scan findings and data collected during evaluations such as serum prostate-specific antigen (PSA) levels, digital rectal examination (DRE), transrectal ultrasound (TRUS), and/or biopsy to confirm prostate cancer. Of a total of 18,393 cases, 106 (0.6%) exhibited abnormal hypermetabolism in the prostate. Additional evaluations were performed in 66 patients. Serum PSA levels were not significantly correlated with maximum standardized uptake values (SUVmax) in all patients (rho 0.483, p=0.132). Prostate biopsies were performed in 15 patients, and prostate cancer was confirmed in 11. The median serum PSA level was 4.8 (0.55-7.06) ng/mL and 127.4 (1.06-495) ng/mL in the benign and prostate cancer groups, respectively. The median SUVmax was higher in the prostate cancer group (mean 10.1, range 3.8-24.5) than in the benign group (mean 4.3, range 3.1-8.8), but the difference was not statistically significant (p=0.078). There was no significant correlation between SUVmax and serum PSA, prostatic volume, or Gleason score. $^{18}F$-FDG PET/CT scans did not reliably differentiate malignant or benign from abnormal uptake lesions in the prostate, and routine prostate biopsy was not usually recommended in patients with abnormal FDG uptake. Nevertheless, patients with incidental prostate uptake on $^{18}F$-FDG PET/CT scans should not be ignored and should be undergo further clinical evaluations, such as PSA and DRE.

• Journal of radiological science and technology
• /
• v.33 no.3
• /
• pp.239-243
• /
• 2010

Even though clinical use DRE, PSA and TRUS for screening while diagnosing prostate cancer early, however, we cannot achieve to diagnose it accurately by one method. Thus, mutual supplements are strongly required in diagnosis. It means that we should identify relationship between prostate volume and serum PSA under different ages for better diagnosis. The subjects(405 men) visited the department of diagnostic radiology in a general university hospital from January 2008 to December 2008, who was going to take the prostatic evaluation by TRUS. 13 men, who did definite diagnosis of prostate cancer before through biopsy, were excluded in this study. All data were expressed as mean and standard deviations by using SPSS 14.0 package programs and were analyzed by using one-way ANOVA to evaluate the effect of different ages. And Scheffe Post hoc comparison is accomplished in order to make significant difference in prostate volume, PSA and PSAD according to ages. Pearson correlation was used for ages, prostate volume, PSA and PSAD. According to examination, the subjects' prostate volume and serum PSA level increase as person's age. We can see significant difference between group over 70 years and group from 40 and 50 years. Moreover, age, prostate volume and serum PSA have significant positive correlation. Even though we can get variations in serum PSA level by changing prostate volume according to ages, it is worthwhile to mention that more strong association for prostate volume is observed than ages in elevation of serum PSA. Therefore, it is strongly recommended to consider prostate volume weightly when it comes to evaluate for men with elevated PSA level. Finally, TRUS is an excellent extra equipment to diagnose prostate cancer because it can contribute to early diagnose and pertinent treatment of prostate cancer.

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.6
• /
• pp.2375-2378
• /
• 2015

Background: The effects of diet on epidemiology of prostate cancer are inconclusive. Therefore a hospitalbased, case-control study was conducted in a rural population of Faisalabad, Pakistan, to examine the impact of dietary factors on risk of cancer development. Materials and Methods: This study was based on 102 confirmed cases of prostate cancer and 204 normal controls. Logistic regression was used to estimate odds ratios and 95% confidence intervals for odds ratios to evaluate the relationship between prostate cancer and diet. Results: Consumption of red meat and fat items significantly increased the prostate cancer risk having odds ratios and 95% confidence intervals of 3.41; 1.46-7.96 and 2.45; 1.17-5.15, respectively. On the other hand, more consumption of vegetables, fluid intake and fruit significantly decreased the prostate cancer risk (odd ratios and corresponding 95% confidence intervals of 0.21; 0.10-0.44, 0.10; 0.05- 0.19 and 0.09; 0.03- 0.23, respectively. Conclusions: The present study supports the hypothesis that frequent consumption of red meat and fat items may increase prostate cancer risk while more intake of fruit, vegetables and fluid intake may protect against prostate cancer in the relatively low risk group in rural Pakistan.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.6
• /
• pp.3897-3901
• /
• 2013

Background: Optimal treatment for prostate cancer remains a challenge worldwide. Recently, T cell immunoglobulin mucin-3 (TIM-3) has been implicated in tumor biology but its contribution prostate cancer remains unclear. The aim of this study was to investigate the role of TIM-3 as a prognostic marker in patients with prostate cancer. Methods: TIM-3 protein expression was determined by immunohistochemistry and Western blotting in 137 prostate cancer tumor samples and paired adjacent benign tissue. We also performed cell proliferation assays using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl- 2H tetrazolium bromide (MTT) and cell invasion assays. The effects of small interfering RNA (siRNA)-mediated knockdown of TIM-3 (TIM-3 siRNA) in two human prostate cancer cell lines were also evaluated. Results: TIM-3 expression was higher in prostate cancer tissue than in the adjacent benign tissue (P<0.001). High TIM-3 expression was an independent predictor of both recurrence-free survival and progression-free survival. TIM-3 protein was expressed in both prostate cancer cell lines and knockdown suppressed their proliferation and invasion capacity. Conclusions: TIM-3 expression is associated with a poor prognosis in prostate cancer. Taken together, our resutlts indicate that TIM-3 is a potential prognostic marker in prostate cancer.

• Journal of radiological science and technology
• /
• v.41 no.4
• /
• pp.313-319
• /
• 2018

The purpose of this study was to investigate the influence of metabolic syndrome (MS) on the lower urinary tract symptoms (LUTS), prostate specific antigen (PSA), and prostate volume in Korean men. We analyzed the data from 2654 men over the age of 40 who visited our health promotion center for regular health checkups. Of the total 2654 men, mean age, PSA level, International Prostate Symptom Score (IPSS), and prostate volume were 54.6 years, 1.21ng/ml, 6.2 points, and 27.8ml, respectively. All examinees were divided into MS group (46.5%, 1235 men) and non-MS group (53.5%, 1419). Age and prostate volume were significantly higher in the MS group. The patients were divided into three groups according to their ages: 40's, 50's, and over 60 years old. Prostate volume of the MS group in the younger age groups (40-49 years and 50-59 years) was significantly larger than that of the non-MS group. However, no difference was revealed in the age group of 60-69 years. No significant differences were found in the PSA level and LUTS between the MS and non-MS groups. In the multivariate regression analysis, central obesity was the strongest risk factor for the enlargement of prostate over 30ml among the metabolic components.